参芪扶正注射液联合恩度治疗中晚期胃癌疗效及对患者免疫功能和生活质量的影响

Shenqi Fuzheng injection in combination with Endostar for treatment of patients with advanced gastric cancer: Curative efficacy and effect on immune function and quality of life

目的:探讨参芪扶正注射液联合重组人血管内皮抑制素(商品名:恩度)治疗中晚期胃癌疗效、不良反应及对患者免疫功能和生活质量的影响,为临床治疗中晚期胃癌提供临床依据.方法:收集青海省人民医院2009-10/2013-10收治的150例中晚期胃癌患者,随机将其分为对照组与观察组各75例.对照组给予恩度和FOLFOX方案治疗,观察组在对照组基础上给予参芪扶正注射液治疗,观察并比较两组患者疗效、不良反应及对患者免疫功能和生活质量的影响.结果:观察组与对照组的治疗有效率分别比较无统计学差异(62.7%vs 56.0%,P>0.05),观察组治疗后肿瘤相关物质群(tumor supplied group of factors,TSGF)、糖链抗原72-4(carbohydrate antigen 72-4,CA72-4)、癌胚抗原(carcino-embryonic antigen,CEA)血清水平均显著低于对照组患者,差异均具有统计学意义(49.37 U/m L±3.24 U/m L vs 54.46U/m L±4.33 U/m L,3.27 U/m L±2.36 U/m L vs8.34 U/m L±2.12 U/m L,0.41 ng/m L±0.24 ng/m L vs 0.48 ng/m L±0.17 ng/m L,均P<0.05).观察组患者在骨髓抑制及中性粒细胞减少方面显著低于对照组患者,差异具有统计学意义(24.0%vs 44.0%,21.3%vs 44.0%,均P<0.05),两组患者其他方面不良反应无显著统计学差异.观察组患者免疫功能与生活质量均显著提高,差异均具有统计学意义(均P<0.05).结论:参芪扶正注射液联合恩度治疗晚期胃癌疗效确切,不良反应降低,患者免疫功能与生活质量得到显著提高,值得临床上进一步研究.

AIM： To assess the curative efficacy of Shenqi Fuzheng injection in combination with Endostar in the treatment of patients with advanced gastric cancer（AGC） as well as the effect on the immune function and quality of life. METHODS： One hundred and fifty AGC patients were randomly and equally divided into two groups： a control group and an observation group. The control group was treated with Endostar in combination with FOLFOX regimen, and the observation group was treated with Shenqi Fuzheng injection on the basis of treatment in the control group. The curative efficacy, toxic side effects, immune function and quality of life were compared for the two groups. RESULTS： The curative efficacy between the observation group and the control group had no significant difference（62.7% vs 56.0%, P〈0.05）. Serum levels of tumor supplied group of factor（TSGF）, carbohydrate antigen 72-4（CA72-4） and carcino-embryonic antigen（CEA） in the observation group were significantly lower than those in the control group after treatment（49.37 U/m L ± 3.24 U/m L vs 54.46 U/m L ± 4.33 U/m L, 3.27 U/m L ± 2.36 U/m L vs 8.34 U/m L ± 2.12 U/m L, 0.41 ng/m L ± 0.24 ng/m L vs 0.48 ng/m L ± 0.17 ng/m L, P 005）. Compared to the control group, the incidences of myelosuppression and neutropenia in the observation group were significantly decreased, and the immune function and quality of life were significantly improved after treatment（24.0% vs 44.0%, 21.3% vs 44.0%, P〈0.05）. CONCLUSION： Shenqi Fuzheng injection in combination with Endostar for AGC is effective, and can significantly improve the immune function and quality of life.